Waldenstrom Macroglobulinemia — Trials

Waldenstrom Macroglobulinemia — Trials · CancerIndex

Clinical trials

Registered studies

308 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 59
Recruiting: 26
Ph III recruiting: 2
Growth YoY: —
Industry share: 39%
Top sponsor: Christian Buske
Termination share: 30.1%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (53)

clinicaltrialsPublishedShowing 1–6 of 6 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT01231412	Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant	completed	Phase 3	174	Fred Hutchinson Cancer CenterOTHER	3	Apr 30, 2026	clinicaltrials
NCT03053440	A Study Comparing BGB-3111 and Ibrutinib in Participants With Waldenström's Macroglobulinemia (WM)(ASPEN)	completed	Phase 3	201	BeiGeneINDUSTRY	12	Oct 26, 2024